Radiolabeled peptide therapies, have demonstrated clinical efficacy in the treatment of neuroendocrine tumors (targeting somatostatin receptors, SSTR) and metastatic castration-resistant prostate cancer (mCRPC) (targeting prostate-specific membrane antigen, PSMA). This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.